Cargando…
Alternative starting regimen with aripiprazole long-acting treatments, a case report
INTRODUCTION: Aripiprazole long-acting treatments can significantly control symptom, improve adherence and reduce the risk of relapse compared to oral drugs. An alternative start-up guideline has recently been approved in several countries that simplifies its administration. OBJECTIVES: To present a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568249/ http://dx.doi.org/10.1192/j.eurpsy.2022.1866 |
_version_ | 1784809601268449280 |
---|---|
author | Huete Naval, M. Serván, B. Expósito Durán, M.E. Albarracin, P. Herrero Pellón, E. Galerón, R. |
author_facet | Huete Naval, M. Serván, B. Expósito Durán, M.E. Albarracin, P. Herrero Pellón, E. Galerón, R. |
author_sort | Huete Naval, M. |
collection | PubMed |
description | INTRODUCTION: Aripiprazole long-acting treatments can significantly control symptom, improve adherence and reduce the risk of relapse compared to oral drugs. An alternative start-up guideline has recently been approved in several countries that simplifies its administration. OBJECTIVES: To present a case report of a patient with schizophrenia treated with alternative starting regimen of aripiprazole long-acting treatment. METHODS: Presentation of a clinical case supported by a non-systematic review of literature. RESULTS: We present the case of a 22-year-old patient diagnosed with schizophrenia, whose symptoms started after the birth of her son, 2 years ago. She has presented a poor clinical evolution, requiring several admissions to our inpatient service after discontinuation of her medication. The patient has taken different antipsychotics, including olanzapine and paliperidone long-acting treatment, which were suspended due to side effects (weight gain and increased prolactin levels). A switch to oral aripiprazole 20mg was made, which showed good response and tolerance. Given the persistence of irregular intake, it was decided to switch to aripiprazole long-acting treatment, applying an alternative initial regime consisting of two doses of aripiprazole long-acting treatments 400mg and one oral aripiprazole 20mg. The patient has since had no delusions or hallucinations and is living independently at home. CONCLUSIONS: The administration of a simplified initial regime with aripiprazole long-acting treatments could improve therapeutic adherence while maintaining the same effectiveness and similar side effects. DISCLOSURE: No significant relationships. |
format | Online Article Text |
id | pubmed-9568249 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95682492022-10-17 Alternative starting regimen with aripiprazole long-acting treatments, a case report Huete Naval, M. Serván, B. Expósito Durán, M.E. Albarracin, P. Herrero Pellón, E. Galerón, R. Eur Psychiatry Abstract INTRODUCTION: Aripiprazole long-acting treatments can significantly control symptom, improve adherence and reduce the risk of relapse compared to oral drugs. An alternative start-up guideline has recently been approved in several countries that simplifies its administration. OBJECTIVES: To present a case report of a patient with schizophrenia treated with alternative starting regimen of aripiprazole long-acting treatment. METHODS: Presentation of a clinical case supported by a non-systematic review of literature. RESULTS: We present the case of a 22-year-old patient diagnosed with schizophrenia, whose symptoms started after the birth of her son, 2 years ago. She has presented a poor clinical evolution, requiring several admissions to our inpatient service after discontinuation of her medication. The patient has taken different antipsychotics, including olanzapine and paliperidone long-acting treatment, which were suspended due to side effects (weight gain and increased prolactin levels). A switch to oral aripiprazole 20mg was made, which showed good response and tolerance. Given the persistence of irregular intake, it was decided to switch to aripiprazole long-acting treatment, applying an alternative initial regime consisting of two doses of aripiprazole long-acting treatments 400mg and one oral aripiprazole 20mg. The patient has since had no delusions or hallucinations and is living independently at home. CONCLUSIONS: The administration of a simplified initial regime with aripiprazole long-acting treatments could improve therapeutic adherence while maintaining the same effectiveness and similar side effects. DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9568249/ http://dx.doi.org/10.1192/j.eurpsy.2022.1866 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Huete Naval, M. Serván, B. Expósito Durán, M.E. Albarracin, P. Herrero Pellón, E. Galerón, R. Alternative starting regimen with aripiprazole long-acting treatments, a case report |
title | Alternative starting regimen with aripiprazole long-acting treatments, a case report |
title_full | Alternative starting regimen with aripiprazole long-acting treatments, a case report |
title_fullStr | Alternative starting regimen with aripiprazole long-acting treatments, a case report |
title_full_unstemmed | Alternative starting regimen with aripiprazole long-acting treatments, a case report |
title_short | Alternative starting regimen with aripiprazole long-acting treatments, a case report |
title_sort | alternative starting regimen with aripiprazole long-acting treatments, a case report |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568249/ http://dx.doi.org/10.1192/j.eurpsy.2022.1866 |
work_keys_str_mv | AT huetenavalm alternativestartingregimenwitharipiprazolelongactingtreatmentsacasereport AT servanb alternativestartingregimenwitharipiprazolelongactingtreatmentsacasereport AT expositoduranme alternativestartingregimenwitharipiprazolelongactingtreatmentsacasereport AT albarracinp alternativestartingregimenwitharipiprazolelongactingtreatmentsacasereport AT herreropellone alternativestartingregimenwitharipiprazolelongactingtreatmentsacasereport AT galeronr alternativestartingregimenwitharipiprazolelongactingtreatmentsacasereport |